Conclusion
The role of Aspirin did not reduce the risk of cardiovascular events and has been considered with low risk for primary prevention of cardiovascular events. However, the present meta-analysis reported no significant risk of Aspirin in the primary prevention of cardiovascular events when compared with placebo in diabetic patients. In addition, we found no significant risk of Aspirin on the primary endpoints of cardiovascular events and cardiovascular mortality over the risk of bleeding outcomes in diabetic patients. However, further investigations of Aspirin combined with other antiplatelet drugs can be conducted to rule out the possible advantages in preventing cardiovascular risk among patients of diabetes.